Fennec swings to FY26 Q2 net income of $1.97 million; net sales rise 78% to $17.1 million year over year
PUBT · 3d ago
Share
Listen to the news
- Fennec reported Q2 2026 net sales of USD 17.1 million, up 78% year over year.
- GAAP net income turned to USD 2 million, or USD 0.06 per share.
- Non-GAAP adjusted EBITDA swung to USD 2.8 million.
- Selling and marketing expense climbed to USD 10.7 million as it expanded its sales organization and PEDMARK awareness initiatives.
- Management cited record PEDMARK demand carrying into Q3 as field sales expansion continues; ASCO 2026 data supported integration without compromising cisplatin activity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110701PRIMZONEFULLFEED9807240) on August 11, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending